Authors: Kaye S, Loveday C, Gibb DM., Newberry A.
Published in: 4th International Congress, November 8ht-12th 1998, Glasgow. P_305
Authors: Aboulker JP, Babiker A, Carrière I, et al.
Published in: AIDS.1998;12(14):F151-F160
Objective To evaluate the toxicity, tolerability and effect on laboratory markers of adding lamivudine (3TC) to nucleoside analogue reverse transcriptase inhibitors (NRTI) in children with HIV-1 infection.
Methods HIV-1-infected children on stable NRTI therapy were randomized to receive 3TC syrup or tablets (4 mg/kg twice daily) or matching placebo in addition to existing therapy.